Used to investigate tissue repair, extracellular-matrix signalling, and regenerative biology in cell-based assays and biochemical models under non-clinical conditions
It is indicated for the treatment of adult patients with R/R LBCL after two or more lines of systemic therapy, including DLBCL, HGBCL, and PMBCL ( Abecma, the first anti-BCMA CAR-T product, was approved on March 26, 2021, and is indicated for treating adult patients with R/R MM after immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and monoclonal antibodies targeting CD38 ( Carvykti, a bi-epitope nanobody-based anti-BCMA CAR-T product, was approved on February 28, 2022, for adults with R/R MM after four or more prior lines of therapy, including IMiDs, PIs, and an anti-CD38 monoclonal antibody ( Aucatzyla, a CD19-directed CAR-T therapy, received approval on November 8, 2024, for treating adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
33,34 A phase 2 clinical study (NCT04313634) using senolytics (D + Q) to treat bone loss in postmenopausal women showed that patients with higher senescent cell burden had a more significant response to D + Q, manifested as a 34% increase in bone formation and an 11% decrease in bone resorption
Throughout your protocol, our team provides ongoing support and monitoring, ensuring your journey toward restored balance is effective and comfortable
